Overview

Newland Global Group (NGG) is delighted to present an investment opportunity, on behalf of our client, within the healthcare sector for the early detection of Breast Cancer via definitive blood test which, could revolutionise the way we prevent and manage breast cancer. 

Our Australian client established in 2010, is commercialising the only definitive diagnostic blood test for the early detection of breast cancer. Breast cancer is the most common form of cancer in women, with over 2 million women worldwide diagnosed with the disease annually. The number of women worldwide qualifying for breast screening in 2018 was 250 Million, and in the USA alone, 39 million mammograms were performed in 2018.

Our clients diagnostic test is superior over the limitations of using mammogram screening for the following reasons:

-        High detection accuracy: Around 90% compared to 60-80% from current screening practices, the current gene tests (BRCA 1&2) are risk assessment test and they do not diagnose the presence of breast cancer

-        Easy access for women, everywhere: Improves access and availability to women of all ages compared to the 40-74 age group currently screened; can be done wherever blood collections are undertaken, capturing rural and remote women

-        High safety: No radiation exposure as it is a simple blood draw

-        High acceptability: Providing a routine blood sample eliminating pain and discomfort associated with mammograms

-        Affordability: Women consumers are very accepting of a price point ‘out of pocket expense’ of up to USD$600 per test. This product is widely accepted/supported within Women’s and Primary Care Physicians groups.

Our client has a solid Intellectual Property (“IP”) position with an exclusive 20-year license to the patent, coupled with a very experienced Board and Executive Management Team with extensive international knowledge in the field of breast cancer.

Funds are to be utilised in a further 600 patient trial in the USA, over the next 6 months; following completion the company will launch the product through the CLIA Labs network in the USA. As a result, our client expects to be revenue generating during 2022. Once being utilised in the CLIA network, our client will be seeking to gain FDA approval for access to the wider pathology labs market and are already in discussions with both Quest and Sonic in the USA.

As a first step to exit, the company will explore the opportunity of commercially licensing this technology to the “Big Pharma and Pathology” groups that are active in this space, before a full exit is accomplished through a trade sale or Nasdaq listing within 3 years.

A conservative market share of 0.85% by 2023 would result in approx. 207,000 blood tests (at USD $250) being performed annually; at a royalty rate of 15%, this would see net royalty revenues at USD $7.8 million (AUD $11.4 million).

We are seeking potential investors to support this equity raising.